Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback